Limits...
Comparison of the efficacy of administering a combination of ezetimibe plus fenofibrate versus atorvastatin monotherapy in the treatment of dyslipidemia.

Kumar SS, Lahey KA, Day A, LaHaye SA - Lipids Health Dis (2009)

Bottom Line: The primary endpoint was the percentage reduction of low-density lipoprotein cholesterol (LDL-C).The difference between the two groups was not statistically significant (p = 0.46).The combination of ezetimibe plus fenofibrate appeared to produce nearly identical alterations in serum lipoprotein levels when compared to monotherapy with 10 mg of atorvastatin.

View Article: PubMed Central - HTML - PubMed

Affiliation: University of Toronto, Division of Endocrinology & Metabolism, Toronto, Ontario, Canada. shoba.sujanakumar@utoronto.ca

ABSTRACT

Background: This trial compares the efficacy of administering a combination of ezetimibe plus fenofibrate as an alternative to statin monotherapy for the treatment of dyslipidemia. In this randomized, unblinded crossover study, 43 patients with documented hypercholesterolemia requiring pharmacotherapy were randomized to receive six weeks of either a combination of 10 mg of ezetimibe plus 160 mg of fenofibrate (combination) or 10 mg of atorvastatin monotherapy (atorvastatin). The primary endpoint was the percentage reduction of low-density lipoprotein cholesterol (LDL-C).

Results: LDL-C decreased by 34.6% with the combination therapy versus 36.7% with atorvastatin monotherapy. The difference between the two groups was not statistically significant (p = 0.46). Both study interventions provided similar improvements in total cholesterol (-25.1% with combination versus -24.6% with atorvastatin, p = 0.806) and high-density lipoproteins (+10.0% with combination versus +8.9% with atorvastatin, p = 0.778). Combination therapy showed a trend towards a greater reduction in triglycerides (-25.4% with combination versus -14.5% with atorvastatin, p = 0.079), although there was no significant difference between the two study interventions in terms of the improvement in the TC:HDL ratio (-29.0% with combination versus -28.7% with atorvastatin, p = 0.904).

Conclusions: The combination of ezetimibe plus fenofibrate appeared to produce nearly identical alterations in serum lipoprotein levels when compared to monotherapy with 10 mg of atorvastatin. Daily treatment with the combination of ezetimibe plus fenofibrate is an acceptable alternative to atorvastatin for the treatment of dyslipidemia in patients who are intolerant of statins.

Show MeSH

Related in: MedlinePlus

Comparison of Ezetimibe Plus Fenofibrate Versus Atorvastatin On LDL-C Reduction Over Time.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC2803170&req=5

Figure 2: Comparison of Ezetimibe Plus Fenofibrate Versus Atorvastatin On LDL-C Reduction Over Time.

Mentions: During the six weeks of treatment, LDL-C decreased by 34.6% (p < 0.001) with the combination therapy versus 36.7% (p < 0.001) with atorvastatin monotherapy (Figure 2 and Table 2). The difference between the two interventions was not statistically significant (2.1 +/- 2.8%, p = 0.46). Both study interventions provided similar improvements in TC (-25.1%, p < 0.001 with combination therapy versus -24.6%, p < 0.001 with atorvastatin monotherapy, p = 0.806 for difference between the two groups) and HDL-C (10.0%, p = 0.002 with combination therapy versus 8.9%, p = 0.006 with atorvastatin monotherapy, p = 0.778 for difference between the two groups). Combination therapy showed a non-significant trend towards a greater reduction in triglycerides (-25.4%, p < 0.001 with combination therapy versus -14.5%, p = 0.002 with atorvastatin monotherapy, p = 0.079 for difference between the two groups), though there was no significant difference between the two study interventions in terms of the improvement in the TC:HDL ratio (-29.0%, p < 0.001 with combination therapy versus -28.7%, p < 0.001 with atorvastatin monotherapy, p = 0.904 for difference between the two groups).


Comparison of the efficacy of administering a combination of ezetimibe plus fenofibrate versus atorvastatin monotherapy in the treatment of dyslipidemia.

Kumar SS, Lahey KA, Day A, LaHaye SA - Lipids Health Dis (2009)

Comparison of Ezetimibe Plus Fenofibrate Versus Atorvastatin On LDL-C Reduction Over Time.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC2803170&req=5

Figure 2: Comparison of Ezetimibe Plus Fenofibrate Versus Atorvastatin On LDL-C Reduction Over Time.
Mentions: During the six weeks of treatment, LDL-C decreased by 34.6% (p < 0.001) with the combination therapy versus 36.7% (p < 0.001) with atorvastatin monotherapy (Figure 2 and Table 2). The difference between the two interventions was not statistically significant (2.1 +/- 2.8%, p = 0.46). Both study interventions provided similar improvements in TC (-25.1%, p < 0.001 with combination therapy versus -24.6%, p < 0.001 with atorvastatin monotherapy, p = 0.806 for difference between the two groups) and HDL-C (10.0%, p = 0.002 with combination therapy versus 8.9%, p = 0.006 with atorvastatin monotherapy, p = 0.778 for difference between the two groups). Combination therapy showed a non-significant trend towards a greater reduction in triglycerides (-25.4%, p < 0.001 with combination therapy versus -14.5%, p = 0.002 with atorvastatin monotherapy, p = 0.079 for difference between the two groups), though there was no significant difference between the two study interventions in terms of the improvement in the TC:HDL ratio (-29.0%, p < 0.001 with combination therapy versus -28.7%, p < 0.001 with atorvastatin monotherapy, p = 0.904 for difference between the two groups).

Bottom Line: The primary endpoint was the percentage reduction of low-density lipoprotein cholesterol (LDL-C).The difference between the two groups was not statistically significant (p = 0.46).The combination of ezetimibe plus fenofibrate appeared to produce nearly identical alterations in serum lipoprotein levels when compared to monotherapy with 10 mg of atorvastatin.

View Article: PubMed Central - HTML - PubMed

Affiliation: University of Toronto, Division of Endocrinology & Metabolism, Toronto, Ontario, Canada. shoba.sujanakumar@utoronto.ca

ABSTRACT

Background: This trial compares the efficacy of administering a combination of ezetimibe plus fenofibrate as an alternative to statin monotherapy for the treatment of dyslipidemia. In this randomized, unblinded crossover study, 43 patients with documented hypercholesterolemia requiring pharmacotherapy were randomized to receive six weeks of either a combination of 10 mg of ezetimibe plus 160 mg of fenofibrate (combination) or 10 mg of atorvastatin monotherapy (atorvastatin). The primary endpoint was the percentage reduction of low-density lipoprotein cholesterol (LDL-C).

Results: LDL-C decreased by 34.6% with the combination therapy versus 36.7% with atorvastatin monotherapy. The difference between the two groups was not statistically significant (p = 0.46). Both study interventions provided similar improvements in total cholesterol (-25.1% with combination versus -24.6% with atorvastatin, p = 0.806) and high-density lipoproteins (+10.0% with combination versus +8.9% with atorvastatin, p = 0.778). Combination therapy showed a trend towards a greater reduction in triglycerides (-25.4% with combination versus -14.5% with atorvastatin, p = 0.079), although there was no significant difference between the two study interventions in terms of the improvement in the TC:HDL ratio (-29.0% with combination versus -28.7% with atorvastatin, p = 0.904).

Conclusions: The combination of ezetimibe plus fenofibrate appeared to produce nearly identical alterations in serum lipoprotein levels when compared to monotherapy with 10 mg of atorvastatin. Daily treatment with the combination of ezetimibe plus fenofibrate is an acceptable alternative to atorvastatin for the treatment of dyslipidemia in patients who are intolerant of statins.

Show MeSH
Related in: MedlinePlus